Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Karyopharm Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding Karyopharm Therapeutics Inc.’s stock price such as:

• Karyopharm Therapeutics Inc.’s current stock price and volume
• Why Karyopharm Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for KPTI from analysts
• KPTI’s stock price momentum as measured by its relative strength

About Karyopharm Therapeutics Inc. (KPTI)

Before we jump into Karyopharm Therapeutics Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Want to learn more about Karyopharm Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Karyopharm Therapeutics Inc..

Karyopharm Therapeutics Inc.’s Stock Price as of Market Close

As of April 24, 2026, 12:00 PM, CST, Karyopharm Therapeutics Inc.’s stock price was $8.485.

Karyopharm Therapeutics Inc. is down 3.03% from its previous closing price of $8.750.

During the last market session, Karyopharm Therapeutics Inc.’s stock traded between $8.400 and $8.890. Currently, there are approximately 17.90 million shares outstanding for Karyopharm Therapeutics Inc..

Karyopharm Therapeutics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Karyopharm Therapeutics Inc. Stock Price History

Karyopharm Therapeutics Inc.’s (KPTI) price is currently up 52.33% so far this month.

During the month of April, Karyopharm Therapeutics Inc.’s stock price has reached a high of $9.670 and a low of $5.390.

Over the last year, Karyopharm Therapeutics Inc. has hit prices as high as $10.990 and as low as $3.650. Year to date, Karyopharm Therapeutics Inc.’s stock is up 15.29%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Karyopharm Therapeutics Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 23, 2026, there were 0 analysts who downgraded Karyopharm Therapeutics Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Karyopharm Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Karyopharm Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Karyopharm Therapeutics Inc. (KPTI) by visiting AAII Stock Evaluator.

Relative Price Strength of Karyopharm Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 23, 2026, Karyopharm Therapeutics Inc. has a weighted four-quarter relative price strength of 10.72%, which translates to a Momentum Score of 81 and is considered to be Very Strong.

Want to learn more about how Karyopharm Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Karyopharm Therapeutics Inc. Stock Price: Bottom Line

As of April 24, 2026, Karyopharm Therapeutics Inc.’s stock price is $8.485, which is down 3.03% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Karyopharm Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.